ClinicalTrials.gg
CompletedNCT00467779Updated Aug 26, 2016Results posted

Study of Cobimetinib in Participants With Solid Tumors

A Phase 1 interventional study of cobimetinib and dextromethorphan in Solid Tumor, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed solid tumor that is or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no known therapies to prolong survival
  • Disease that is measurable according to (RECIST)
  • Adequate organ and marrow function
  • Sexually active participants must use medically acceptable methods of during the course of the study and at least 11 days after the last dose of study treatment
  • Female participants of must have a negative serum pregnancy test at screening
  • No other history of/or ongoing that would potentially interfere with the interpretation of the pharmacodynamic or efficacy assays

Exclusion criteria

Exclusion Criteria:

  • Anticancer treatment (e.g., chemotherapy, radiotherapy, cytokines, or hormones) within 28 days (6 weeks for nitrosoureas or mitomycin C, or 14 days for hormonal therapy or kinase inhibitors) before the first dose of study drug
  • The participant has not recovered to Grade \</=1 from adverse events (AEs) or to within 10% of baseline values due to or other agents administered more than 28 days prior to study enrollment
  • The participant has received another investigational agent within 28 days of the first dose of study drug
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
  • The participant is pregnant or breastfeeding
  • The participant is known to be positive for the (HIV)
  • Allergy or to components of the cobimetinib formulation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)

    Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment \[21/7 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.

    Drug: cobimetinib

  • Experimental
    Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)

    Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment \[14/14 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.

    Drug: cobimetinib

  • Experimental
    Stage 2: Cobimetinib Expansion (21/7 Schedule)

    Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment \[21/7 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.

    Drug: cobimetinib

  • Experimental
    Stage 2 A: Cobimetinib Expansion (14/14 Schedule)

    Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment \[14/14 schedule\]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.

    Drug: cobimetinib

  • Experimental
    Stage 3: Cobimetinib+Midazolam+Dextromethorphan

    Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).

    Drug: cobimetinib · Drug: dextromethorphan · Drug: midazolam

Interventions

  • Repeating oral dose

    Also known as: GDC-0973/XL518

  • In Stage III only: single dose of dextromethorphan

  • In Stage III only: single dose of midazolam

06

What researchers measure

Primary outcomes

  1. Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs)

    Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the cohort review committee (CRC), was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection

    Time frame: Stage 1 and 1A: Days 1 to 28 of Cycle 1

  2. Stage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule

    AEs were graded according to the NCI-CTCAE v3.0. A DLT was determined from clinical findings during the Study Treatment Period (Cycle 1, Days 1). MTD was defined as the dose at which no DLTs were observed. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection

    Time frame: Stage 1: Days 1 to 28 of Cycle 1

  3. Stage 1A: MTD of Cobimetinib in 14/14 Schedule

    AEs were graded according to NCI-CTCAE v3.0. A DLT was the basis for determining MTD in Stage 1A participants. The participants of Stage 1A are dose-escalation cohorts, starting at the MTD of the 21/7 schedule, were treated on a 14/14 schedule to determine the MTD. A DLT was defined as either of the following occurring during the Study Treatment Period: Occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants to risk of irreversible medical harm; Nonhematologic toxicity: Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment; Hematologic toxicity: Grade 4 thrombocytopenia. Grade 4 neutropenia of more than 4 days' duration; Grade 4 neutropenia of any duration with fever or documented infection. AEs (Grade 3 or higher) for which a clinical cause unrelated to cobimetinib was evident was not considered DLTs.

    Time frame: Stage 1A: Days 1 to 28 of Cycle 1

  4. Stage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 1

    Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on Day 1, Cycle 1 in Stage 1 and was measured as nanograms per milliliter (ng/mL).

    Time frame: Stage 1: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1 and pre-dose on Cycle 1 Day 2

  5. Stage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 1

    The area under the concentrations-time curve (AUC0-24) was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samples. AUC is measured as hours times nanograms per milliliter (h\*ng/mL).

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  6. Stage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 1

    Tmax is defined as the time to reach Cmax during stage 1 at Day 1 Cycle 1.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1 and pre-dose on Cycle 1 Day 2

Secondary outcomes

  1. Stage 1: Tmax of Cobimetinib at Steady State

    Tmax is defined as the time to reach Cmax during stage 1 in steady state. Steady state was reached when overall intake of cobimetinib was in dynamic equilibrium with its elimination.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  2. Stage 1: AUC 0-24 of Cobimetinib at Steady State

    The area under the AUC0-24 for steady state in stage 1 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  3. Stage 1: AUC 0-24/D of Cobimetinib at Steady State

    AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  4. Stage 1: Accumulation Ratio of Cobimetinib at Steady State

    Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1, Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  5. Stage 1: Apparent Clearance of Cobimetinib at Steady State

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  6. Stage 1: Half-Life (t1/2) of Cobimetinib at Steady State

    t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1 in steady state.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  7. Stage 1: Cmax of Cobimetinib at Steady State

    Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1 and was measured at steady state in ng/mL.

    Time frame: Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)

  8. Stage 1A: Tmax of Cobimetinib at Cycle 1 Day 1

    Tmax is defined as the time to reach Cmax during stage 1A at Day 1.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  9. Stage 1A: Cmax of Cobimetinib at Cycle 1 Day 1

    Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on on Day 1 in Stage 1A and was measured as ng/mL.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  10. Stage 1A: AUC 0-24 of Cobimetinib at Cycle 1 Day 1

    AUC0-24 for stage 1A was calculated on Day 1 with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  11. Stage 1A: t1/2 of Cobimetinib at Steady State

    t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1A in steady state.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  12. Stage 1A: Tmax of Cobimetinib at Steady State

    Tmax is defined as the time to reach Cmax during stage 1A in steady state.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  13. Stage 1A: Apparent Clearance of Cobimetinib at Steady State

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  14. Stage 1A: Accumulation Ratio of Cobimetinib at Steady State

    Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  15. Stage 1A: AUC 0-24 of Cobimetinib at Steady State

    The area under the AUC0-24 for steady state in stage 1A was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  16. Stage 1A: AUC 0-24/D of Cobimetinib at Steady State

    AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  17. Stage 1A: Cmax of Cobimetinib at Steady State

    Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1A and was measured in steady state as ng/mL.

    Time frame: Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)

  18. Stage 2: Cmax of Cobimetinib at Cycle 1 Day 1

    Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 2 and was measured in ng/mL.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  19. Stage 2:AUC 0-24 of Cobimetinib at Cycle 1 Day 1

    The area under the AUC0-24 on Day 1 in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  20. Stage 2: Tmax of Cobimetinib at Cycle 1 Day 1

    Tmax is defined as the time to reach Cmax during stage 2 on Day 1.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2

  21. Stage 2: Tmax of Cobimetinib at Steady State

    Tmax is defined as the time to reach Cmax during stage 2 in steady state.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28

  22. Stage 2: AUC 0-24 of Cobimetinib at Steady State

    The area under the AUC0-24 for steady state in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28

  23. Stage 2: AUC 0-24/D of Cobimetinib at Steady State

    AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28

  24. Stage 2: Accumulation Ratio of Cobimetinib at Steady State

    Accumulation ratio is AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28

  25. Stage 2: Apparent Clearance of Cobimetinib at Steady State

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28

  26. Stage 2:Half-Life of Cobimetinib at Steady State

    T1/2 half-life of cobimetinib measured over the terminal phase by noncompartmental analysis.

    Time frame: Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28

  27. Stage 2A: AUC 0-24/D of Cobimetinib at Steady State

    AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

    Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28

  28. Stage 2A: Accumulation Ratio of Cobimetinib at Steady State

    Accumulation Ratio AUC0-24 is ratio of AUC on Day 20: Day 1.

    Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28

  29. Stage 2A: Apparent Clearance of Cobimetinib at Steady State

    Apparent clearance is the plasma clearance of absorbed drug.

    Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28

  30. Stage 2A: Half-Life of Cobimetinib at Steady State

    Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28

  31. Stage 2A: Tmax of Cobimetinib at Steady State

    Tmax is defined as the time to reach Cmax during stage 2A in steady state.

    Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28

  32. Stage 2A: Cmax of Cobimetinib at Steady State

    Cmax is the maximum plasma concentration achieved following the Day 20 dose in Stage 2A.

    Time frame: Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28

  33. Stage III: Cmax of Dextromethorphan

    Cmax is defined as maximum observed plasma concentration and was determined both in the presence (Cycle 1 Day 15) and absence of cobimetinib (Cycle 1 Day 1).

    Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1

  34. Stage III: AUC 0-24 of Dextromethorphan

    AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was determined both in presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

    Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1

  35. Stage III: AUC 0-inf of Dextromethorphan

    AUC0-inf is AUC from time 0 to infinity and was calculated both in presence Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

    Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1

  36. Stage III: Cmax of Midazolam

    Cmax is the maximum observed plasma concentration and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

    Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1

  37. Stage III: AUC0-24 of Midazolam

    AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was calculated both in the presence (Cycle 1 Day 15) and absence (CXycle 1 Day 1) of cobimetinib.

    Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1

  38. Stage III: AUC0-inf of Midazolam

    AUC0-inf is the AUC from time 0 to infinity and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

    Time frame: Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1

07

Results

Posted Jul 22, 2016

Participant flow

Stage 1
Participant flow — Stage 1
MilestoneStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
Started433336770000000
Completed000001000000000
Not completed433335770000000
Withdrew: Adverse event100001210000000
Withdrew: Disease progression222322450000000
Withdrew: Unspecified reason101012000000000
Withdrew: Physician decision010000000000000
Withdrew: Withdrawal by subject000000110000000
Stage 1A
Participant flow — Stage 1A
MilestoneStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
Started000000000338600
Completed000000000000000
Not completed000000000338600
Withdrew: Adverse event000000000000100
Withdrew: Death000000000001100
Withdrew: Disease progression000000000225200
Withdrew: Physician decision000000000100000
Withdrew: Withdrawal by subject000000000011100
Withdrew: Unspecified reason000000000001100
Stage 2
Participant flow — Stage 2
MilestoneStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
Started0000000021000000
Completed000000000000000
Not completed0000000021000000
Withdrew: Adverse event000000001000000
Withdrew: Death000000001000000
Withdrew: Disease progression0000000016000000
Withdrew: Unspecified reason000000003000000
Stage 2A
Participant flow — Stage 2A
MilestoneStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
Started0000000000000220
Completed000000000000010
Not completed0000000000000210
Withdrew: Adverse event000000000000020
Withdrew: Death000000000000010
Withdrew: Disease progression0000000000000100
Withdrew: Unspecified reason000000000000070
Withdrew: Withdrawal by subject000000000000010
Stage 3
Participant flow — Stage 3
MilestoneStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
Started0000000000000020
Completed000000000000003
Not completed0000000000000017
Withdrew: Adverse event000000000000002
Withdrew: Death000000000000001
Withdrew: Disease progression000000000000009
Withdrew: Unspecified reason000000000000005

Outcome measures

PrimaryStage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs)

Adverse events (AE) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the cohort review committee (CRC), was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection

Time frame:
Stage 1 and 1A: Days 1 to 28 of Cycle 1
Reported as:
Number · participants
Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs)
participantsStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1 and 1A: Number of Participants With Dose Limiting Toxicities (DLTs)000001120002
PrimaryStage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule

AEs were graded according to the NCI-CTCAE v3.0. A DLT was determined from clinical findings during the Study Treatment Period (Cycle 1, Days 1). MTD was defined as the dose at which no DLTs were observed. DLT was defined as either of the following occurring during the Study Treatment Period. The occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants in higher dose cohorts to risk of irreversible medical harm or require medical treatment to avoid irreversible medical harm or non-hematologic toxicity * Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment Hematologic toxicity * Grade 4 thrombocytopenia * Grade 4 neutropenia of greater than or equal to (≥) 4 days' duration * Grade 4 neutropenia of any duration with fever or documented infection

Time frame:
Stage 1: Days 1 to 28 of Cycle 1
Reported as:
Number · milligrams (mg)
Stage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule
milligrams (mg)Stage 1 All Cohorts (21/7)
Stage 1: Maximum Tolerated Dose (MTD) of Cobimetinib in 21/7 Schedule60
PrimaryStage 1A: MTD of Cobimetinib in 14/14 Schedule

AEs were graded according to NCI-CTCAE v3.0. A DLT was the basis for determining MTD in Stage 1A participants. The participants of Stage 1A are dose-escalation cohorts, starting at the MTD of the 21/7 schedule, were treated on a 14/14 schedule to determine the MTD. A DLT was defined as either of the following occurring during the Study Treatment Period: Occurrence of a drug-related AE that, in the opinion of the CRC, was of potential clinical significance such that further dose escalation would expose participants to risk of irreversible medical harm; Nonhematologic toxicity: Grade 3 or 4 events, including Grade 3 nausea and/or vomiting and/or Grade 3 diarrhea, despite prophylaxis and/or treatment; Hematologic toxicity: Grade 4 thrombocytopenia. Grade 4 neutropenia of more than 4 days' duration; Grade 4 neutropenia of any duration with fever or documented infection. AEs (Grade 3 or higher) for which a clinical cause unrelated to cobimetinib was evident was not considered DLTs.

Time frame:
Stage 1A: Days 1 to 28 of Cycle 1
Reported as:
Number · mg
Stage 1A: MTD of Cobimetinib in 14/14 Schedule
mgStage 1A - All Cohorts (14/14)
Stage 1A: MTD of Cobimetinib in 14/14 Schedule100
PrimaryStage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 1

Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on Day 1, Cycle 1 in Stage 1 and was measured as nanograms per milliliter (ng/mL).

Time frame:
Stage 1: Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1 and pre-dose on Cycle 1 Day 2
Reported as:
Geometric mean · ng/mL
Stage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 1
ng/mLStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Maximum Observed Concentration (Cmax) of Cobimetinib at Day 1, Cycle 14.51 ± 5.86.92 ± 3.818.3 ± 13.018.8 ± 5.130.8 ± 69.071.7 ± 57.0163.0 ± 79.0261.0 ± 110.0
PrimaryStage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 1

The area under the concentrations-time curve (AUC0-24) was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samples. AUC is measured as hours times nanograms per milliliter (h\*ng/mL).

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Geometric mean · h*ng/mL
Stage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 1
h*ng/mLStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Area Under the Plasma Cobimetinib Concentration Curve From Time 0 to 24 Hours (AUC 0-24) Day 1, Cycle 156.2 ± 65.068.0 ± 47.0203.0 ± 130.0242.0 ± 64.0440.0 ± 870.0785.0 ± 560.01620.0 ± 830.03060.0 ± 950.0
PrimaryStage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 1

Tmax is defined as the time to reach Cmax during stage 1 at Day 1 Cycle 1.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1 and pre-dose on Cycle 1 Day 2
Reported as:
Median · hours
Stage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 1
hoursStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Time to Maximum Concentration (Tmax) of Cobimetinib at Day 1, Cycle 12.0 (2.0 to 8.0)1.0 (1.0 to 2.0)1.5 (1.0 to 1.5)3.0 (1.0 to 4.0)4.0 (2.0 to 4.0)2.5 (1.5 to 6.0)2.0 (1.0 to 4.0)2.0 (1.5 to 2.0)
SecondaryStage 1: Tmax of Cobimetinib at Steady State

Tmax is defined as the time to reach Cmax during stage 1 in steady state. Steady state was reached when overall intake of cobimetinib was in dynamic equilibrium with its elimination.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Median · hours
Stage 1: Tmax of Cobimetinib at Steady State
hoursStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Tmax of Cobimetinib at Steady State4.0 (2.0 to 4.0)1.0 (1.0 to 2.0)2.25 (1.5 to 3.0)4.0 (3.0 to 4.0)3.0 (3.0 to 3.0)2.0 (1.5 to 3.0)3.0 (1.5 to 4.0)2.5 (2.0 to 4.0)
SecondaryStage 1: AUC 0-24 of Cobimetinib at Steady State

The area under the AUC0-24 for steady state in stage 1 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Mean · h*ng/mL
Stage 1: AUC 0-24 of Cobimetinib at Steady State
h*ng/mLStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: AUC 0-24 of Cobimetinib at Steady State202.0 ± 158.0288.0 ± 200.0411.0 ± 199.0763.0 ± 168.0886.05370.0 ± 4600.06250.0 ± 3540.010500.0 ± 10500.0
SecondaryStage 1: AUC 0-24/D of Cobimetinib at Steady State

AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Mean · ng*hr/mL/mg
Stage 1: AUC 0-24/D of Cobimetinib at Steady State
ng*hr/mL/mgStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: AUC 0-24/D of Cobimetinib at Steady State62.4 ± 36.334 ± 16.928.2 ± 8.4376.3 ± 16.844.3134 ± 115104 ± 59.1132 ± 131
SecondaryStage 1: Accumulation Ratio of Cobimetinib at Steady State

Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 1, Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Mean · ratio
Stage 1: Accumulation Ratio of Cobimetinib at Steady State
ratioStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Accumulation Ratio of Cobimetinib at Steady State3.56 ± 1.763.66 ± 0.9012.65 ± 0.8863.23 ± 1.032.963.61 ± 2.272.87 ± 0.7873.26 ± 2.1
SecondaryStage 1: Apparent Clearance of Cobimetinib at Steady State

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Mean · Liters per hour (L/hr)
Stage 1: Apparent Clearance of Cobimetinib at Steady State
Liters per hour (L/hr)Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Apparent Clearance of Cobimetinib at Steady State22.4 ± 17.234.0 ± 14.237.1 ± 11.113.5 ± 2.7122.614.0 ± 10.111.8 ± 5.7111.6 ± 5.42
SecondaryStage 1: Half-Life (t1/2) of Cobimetinib at Steady State

t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1 in steady state.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Median · hours
Stage 1: Half-Life (t1/2) of Cobimetinib at Steady State
hoursStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Half-Life (t1/2) of Cobimetinib at Steady State80.0 (80.0 to 80.0)64.0 (51.5 to 73)47.8 (46.5 to 49.1)66.0 (34.0 to 67.5)50.5 (50.5 to 50.5)41.3 (34.2 to 62.4)51.3 (23.1 to 61.4)60.0 (33.5 to 65.4)
SecondaryStage 1: Cmax of Cobimetinib at Steady State

Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1 and was measured at steady state in ng/mL.

Time frame:
Stage 1: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12-18 hours post-dose on Cycle 1 Day 21, 24, 48, and 72 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22, 23, and 24, respectively)
Reported as:
Mean · ng/mL
Stage 1: Cmax of Cobimetinib at Steady State
ng/mLStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)
Stage 1: Cmax of Cobimetinib at Steady State13.5 ± 9.5319.8 ± 15.228.7 ± 8.6353.0 ± 5.454.7341.0 ± 244.0401.0 ± 214.0641.0 ± 514.0
SecondaryStage 1A: Tmax of Cobimetinib at Cycle 1 Day 1

Tmax is defined as the time to reach Cmax during stage 1A at Day 1.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Median · hours
Stage 1A: Tmax of Cobimetinib at Cycle 1 Day 1
hoursStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: Tmax of Cobimetinib at Cycle 1 Day 13.0 (1.5 to 4.0)4.0 (2.0 to 24)3.5 (1.5 to 6)2.5 (2.0 to 4.0)
SecondaryStage 1A: Cmax of Cobimetinib at Cycle 1 Day 1

Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib on on Day 1 in Stage 1A and was measured as ng/mL.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Mean · ng/mL
Stage 1A: Cmax of Cobimetinib at Cycle 1 Day 1
ng/mLStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: Cmax of Cobimetinib at Cycle 1 Day 178.4 ± 88.0167.0 ± 63.0258.0 ± 140.0533.0 ± 347.0
SecondaryStage 1A: AUC 0-24 of Cobimetinib at Cycle 1 Day 1

AUC0-24 for stage 1A was calculated on Day 1 with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Mean · h*ng/mL
Stage 1A: AUC 0-24 of Cobimetinib at Cycle 1 Day 1
h*ng/mLStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: AUC 0-24 of Cobimetinib at Cycle 1 Day 11140 ± 11502130 ± 70.14020 ± 20007190 ± 3640
SecondaryStage 1A: t1/2 of Cobimetinib at Steady State

t1/2 is the half-life of cobimetinib measured over the terminal phase by noncompartmental analysis in stage 1A in steady state.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Median · hours
Stage 1A: t1/2 of Cobimetinib at Steady State
hoursStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: t1/2 of Cobimetinib at Steady State59.4 (59.4 to 59.4)44.1 (44.1 to 44.1)51.6 (48.1 to 71.1)47.7 (47.7 to 47.7)
SecondaryStage 1A: Tmax of Cobimetinib at Steady State

Tmax is defined as the time to reach Cmax during stage 1A in steady state.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Median · hours
Stage 1A: Tmax of Cobimetinib at Steady State
hoursStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: Tmax of Cobimetinib at Steady State2.0 (1.5 to 4.0)2.0 (2.0 to 6.0)3 (1.5 to 4.0)6 (2.0 to 6.0)
SecondaryStage 1A: Apparent Clearance of Cobimetinib at Steady State

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Mean · L/hr
Stage 1A: Apparent Clearance of Cobimetinib at Steady State
L/hrStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: Apparent Clearance of Cobimetinib at Steady State25.1 ± 13.514.9 ± 8.3321.9 ± 20.36.9 ± 3.22
SecondaryStage 1A: Accumulation Ratio of Cobimetinib at Steady State

Accumulation Ratio: AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Mean · ratio
Stage 1A: Accumulation Ratio of Cobimetinib at Steady State
ratioStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: Accumulation Ratio of Cobimetinib at Steady State2.32 ± 0.4483.14 ± 1.772.6 ± 2.325.15 ± 2.08
SecondaryStage 1A: AUC 0-24 of Cobimetinib at Steady State

The area under the AUC0-24 for steady state in stage 1A was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Mean · h*ng/mL
Stage 1A: AUC 0-24 of Cobimetinib at Steady State
h*ng/mLStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: AUC 0-24 of Cobimetinib at Steady State2990.0 ± 1750.06740.0 ± 3830.011500.0 ± 10500.021500.0 ± 11300.0
SecondaryStage 1A: AUC 0-24/D of Cobimetinib at Steady State

AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Mean · ng*hr/mL/mg
Stage 1A: AUC 0-24/D of Cobimetinib at Steady State
ng*hr/mL/mgStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: AUC 0-24/D of Cobimetinib at Steady State49.8 ± 29.284.2 ± 47.8115.0 ± 105.0172.0 ± 90.4
SecondaryStage 1A: Cmax of Cobimetinib at Steady State

Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 1A and was measured in steady state as ng/mL.

Time frame:
Stage 1A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24, 48, 72 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15, 16, and 17, respectively)
Reported as:
Mean · ng/mL
Stage 1A: Cmax of Cobimetinib at Steady State
ng/mLStage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)
Stage 1A: Cmax of Cobimetinib at Steady State180.0 ± 101.0494.0 ± 175.0640.0 ± 511.01160.0 ± 540.0
SecondaryStage 2: Cmax of Cobimetinib at Cycle 1 Day 1

Cmax is defined as the maximum plasma concentration achieved after administration of cobimetinib in Stage 2 and was measured in ng/mL.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Geometric mean · ng/mL
Stage 2: Cmax of Cobimetinib at Cycle 1 Day 1
ng/mLStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: Cmax of Cobimetinib at Cycle 1 Day 1184.0 ± 160.0
SecondaryStage 2:AUC 0-24 of Cobimetinib at Cycle 1 Day 1

The area under the AUC0-24 on Day 1 in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Geometric mean · h*ng/mL
Stage 2:AUC 0-24 of Cobimetinib at Cycle 1 Day 1
h*ng/mLStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2:AUC 0-24 of Cobimetinib at Cycle 1 Day 13060.0 ± 2110.0
SecondaryStage 2: Tmax of Cobimetinib at Cycle 1 Day 1

Tmax is defined as the time to reach Cmax during stage 2 on Day 1.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 1, pre-dose on Cycle 1 Day 2
Reported as:
Median · hours
Stage 2: Tmax of Cobimetinib at Cycle 1 Day 1
hoursStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: Tmax of Cobimetinib at Cycle 1 Day 13.0 (1.0 to 6.0)
SecondaryStage 2: Tmax of Cobimetinib at Steady State

Tmax is defined as the time to reach Cmax during stage 2 in steady state.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Reported as:
Median · hours
Stage 2: Tmax of Cobimetinib at Steady State
hoursStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: Tmax of Cobimetinib at Steady State4.0 (1.5 to 6.0)
SecondaryStage 2: AUC 0-24 of Cobimetinib at Steady State

The area under the AUC0-24 for steady state in stage 2 was calculated with the measured data points from the time of administration of cobimetinib up to 24 h after administration by the trapezoidal formula. AUC 0-24 is the truncated AUC over a 24-hour sampling interval. The concentration-time curve is the result of time points of blood sampling and its measured concentration of free cobimetinib in the blood samplings.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Reported as:
Geometric mean · h*ng/mL
Stage 2: AUC 0-24 of Cobimetinib at Steady State
h*ng/mLStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: AUC 0-24 of Cobimetinib at Steady State10200.0 ± 5630.0
SecondaryStage 2: AUC 0-24/D of Cobimetinib at Steady State

AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Reported as:
Geometric mean · h*ng/mL
Stage 2: AUC 0-24/D of Cobimetinib at Steady State
h*ng/mLStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: AUC 0-24/D of Cobimetinib at Steady State102.0 ± 56.3
SecondaryStage 2: Accumulation Ratio of Cobimetinib at Steady State

Accumulation ratio is AUC0-24 at steady state divided by AUC0-24 on Cycle 1 Day 1. It was calculated only for participants who had a quantifiable AUC 0-24 at steady state.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Reported as:
Geometric mean · ratio
Stage 2: Accumulation Ratio of Cobimetinib at Steady State
ratioStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: Accumulation Ratio of Cobimetinib at Steady State2.5 ± 0.9
SecondaryStage 2: Apparent Clearance of Cobimetinib at Steady State

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. Apparent clearance was calculated only for participants who had a quantifiable AUC 0-24 in steady state.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Reported as:
Mean · L/hr
Stage 2: Apparent Clearance of Cobimetinib at Steady State
L/hrStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2: Apparent Clearance of Cobimetinib at Steady State9.8 ± 9.9
SecondaryStage 2:Half-Life of Cobimetinib at Steady State

T1/2 half-life of cobimetinib measured over the terminal phase by noncompartmental analysis.

Time frame:
Stage 2: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 21, 24 hours post Cycle 1 Day 21 dose (Cycle 1 Day 22), and between Cycle 1 Days 26-28
Reported as:
Median · hours
Stage 2:Half-Life of Cobimetinib at Steady State
hoursStage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)
Stage 2:Half-Life of Cobimetinib at Steady State53.4 (45.3 to 68.3)
SecondaryStage 2A: AUC 0-24/D of Cobimetinib at Steady State

AUC 0-24/D is the dose normalized truncated AUC over a 24-hour sampling interval.

Time frame:
Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Reported as:
Mean · h*ng/mL
Stage 2A: AUC 0-24/D of Cobimetinib at Steady State
h*ng/mLStage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)
Stage 2A: AUC 0-24/D of Cobimetinib at Steady State84.8 ± 52.0
SecondaryStage 2A: Accumulation Ratio of Cobimetinib at Steady State

Accumulation Ratio AUC0-24 is ratio of AUC on Day 20: Day 1.

Time frame:
Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Reported as:
Mean · ratio
Stage 2A: Accumulation Ratio of Cobimetinib at Steady State
ratioStage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)
Stage 2A: Accumulation Ratio of Cobimetinib at Steady State2.3 ± 1.2
SecondaryStage 2A: Apparent Clearance of Cobimetinib at Steady State

Apparent clearance is the plasma clearance of absorbed drug.

Time frame:
Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Reported as:
Mean · L/hr
Stage 2A: Apparent Clearance of Cobimetinib at Steady State
L/hrStage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)
Stage 2A: Apparent Clearance of Cobimetinib at Steady State11.8 ± 5.2
SecondaryStage 2A: Half-Life of Cobimetinib at Steady State
Time frame:
Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Reported as:
Median · hours
Stage 2A: Half-Life of Cobimetinib at Steady State
hoursStage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)
Stage 2A: Half-Life of Cobimetinib at Steady State42.7 (27.8 to 69.6)
SecondaryStage 2A: Tmax of Cobimetinib at Steady State

Tmax is defined as the time to reach Cmax during stage 2A in steady state.

Time frame:
Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Reported as:
Median · hours
Stage 2A: Tmax of Cobimetinib at Steady State
hoursStage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)
Stage 2A: Tmax of Cobimetinib at Steady State3.0 (1.0 to 6.0)
SecondaryStage 2A: Cmax of Cobimetinib at Steady State

Cmax is the maximum plasma concentration achieved following the Day 20 dose in Stage 2A.

Time frame:
Stage 2A: Pre-dose & 0.5, 1, 1.5, 2, 3, 4, 6 hours post-dose on Cycle 1 Day 14, 24 hours post Cycle 1 Day 14 dose (Cycle 1 Day 15), and between Cycle 1 Days 26-28
Reported as:
Geometric mean · ng/mL
Stage 2A: Cmax of Cobimetinib at Steady State
ng/mLStage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)
Stage 2A: Cmax of Cobimetinib at Steady State315.0 ± 220.0
SecondaryStage III: Cmax of Dextromethorphan

Cmax is defined as maximum observed plasma concentration and was determined both in the presence (Cycle 1 Day 15) and absence of cobimetinib (Cycle 1 Day 1).

Time frame:
Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Reported as:
Geometric mean · ng/mL
Stage III: Cmax of Dextromethorphan
ng/mLStage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
With cobimetinib - Cycle 1 Day 15(n=17)3.44 ± 150.0
Without cobimetinib - Cycle 1 Day 1 (n=20)3.16 ± 273.0
SecondaryStage III: AUC 0-24 of Dextromethorphan

AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was determined both in presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

Time frame:
Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Reported as:
Geometric mean · h*ng/mL
Stage III: AUC 0-24 of Dextromethorphan
h*ng/mLStage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
With cobimetinib - Cycle 1 Day 1 (n=17)24.8 ± 180.0
Without cobimetinib - Cycle 1 Day1 (n=19)25.8 ± 240
SecondaryStage III: AUC 0-inf of Dextromethorphan

AUC0-inf is AUC from time 0 to infinity and was calculated both in presence Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

Time frame:
Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Reported as:
Geometric mean · h*ng/mL
Stage III: AUC 0-inf of Dextromethorphan
h*ng/mLStage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
With cobimetinib - Cycle 1 Day 15 (n=13)29.1 ± 250.0
Without cobimetinib - Cycle 1 Day1 (n=19)18.9 ± 124.0
SecondaryStage III: Cmax of Midazolam

Cmax is the maximum observed plasma concentration and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

Time frame:
Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Reported as:
Geometric mean · ng/mL
Stage III: Cmax of Midazolam
ng/mLStage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
With cobimetinib - Cycle 1 Day15 (n=17)11.5 ± 64.0
Without cobimetinib - Cycle 1 Day 1(n=20)10.9 ± 79.0
SecondaryStage III: AUC0-24 of Midazolam

AUC0-24 is the area under the plasma drug concentration curve over a 24-hour sampling interval and was calculated both in the presence (Cycle 1 Day 15) and absence (CXycle 1 Day 1) of cobimetinib.

Time frame:
Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Reported as:
Geometric mean · h*ng/mL
Stage III: AUC0-24 of Midazolam
h*ng/mLStage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
With cobimetinib - Cycle 1 Day 15 (n=14)33.0 ± 74.0
Without cobimetinib - Cycle 1 Day 1 (n=11)33.4 ± 88.0
SecondaryStage III: AUC0-inf of Midazolam

AUC0-inf is the AUC from time 0 to infinity and was calculated both in the presence (Cycle 1 Day 15) and absence (Cycle 1 Day 1) of cobimetinib.

Time frame:
Stage III: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, and 24 hours after dextromethorphan administration on Days 1 and 15 of Cycle 1
Reported as:
Geometric mean · h*ng/mL
Stage III: AUC0-inf of Midazolam
h*ng/mLStage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
With cobimetinib - Cycle 1 Day 15 (n=17)34.9 ± 77.0
Without cobimetinib Cycle 1 Day 1 (n=19)35.7 ± 91.0

Adverse events

Collected over AEs were recorded from the Day 1 of treatment period until the 30 plus or minus 4 days after the last treatment (up to approximately 6 years) .. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)—2/4 (50%)4/4 (100%)
Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)—0/3 (0%)3/3 (100%)
Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)—1/3 (33.3%)3/3 (100%)
Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)—0/3 (0%)3/3 (100%)
Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)—1/3 (33.3%)3/3 (100%)
Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)—3/6 (50%)6/6 (100%)
Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)—3/7 (42.9%)7/7 (100%)
Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)—5/7 (71.4%)7/7 (100%)
Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)—7/21 (33.3%)20/21 (95.2%)
Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)—0/3 (0%)3/3 (100%)
Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)—1/3 (33.3%)3/3 (100%)
Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)—4/8 (50%)8/8 (100%)
Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)—3/6 (50%)6/6 (100%)
Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)—11/22 (50%)21/22 (95.5%)
Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan—8/20 (40%)18/20 (90%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
AnaemiaBlood and lymphatic system disorders1/40/31/30/30/31/60/70/70/210/30/30/80/60/220/20
Supraventricular tachycardiaCardiac disorders0/40/30/30/31/30/60/70/70/210/30/30/80/60/220/20
DiarrhoeaGastrointestinal disorders0/40/30/30/30/30/60/71/70/210/31/30/80/60/220/20
Gastrointestinal haemorrhageGastrointestinal disorders0/40/31/30/30/30/60/70/70/210/30/30/80/61/220/20
Faecal incontinenceGastrointestinal disorders0/40/30/30/31/30/60/70/70/210/30/30/80/60/220/20
Abdominal painGastrointestinal disorders1/40/30/30/30/30/60/70/70/210/30/30/80/60/221/20
IleusGastrointestinal disorders1/40/30/30/30/30/60/70/70/210/30/30/80/60/221/20
Generalised oedemaGeneral disorders1/40/30/30/30/30/60/70/70/210/30/30/80/60/220/20
Bile duct obstructionHepatobiliary disorders1/40/30/30/30/31/60/70/70/210/30/30/80/61/220/20
DehydrationMetabolism and nutrition disorders1/40/30/30/30/31/60/71/70/210/30/30/80/60/220/20
Most frequent other events
Showing 10 of 256
Most frequent other events
EventStage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+Dextromethorphan
DiarrhoeaGastrointestinal disorders2/41/31/32/32/33/64/74/713/211/31/36/86/617/2212/20
NauseaGastrointestinal disorders1/40/30/32/30/31/63/73/77/210/32/36/81/69/224/20
FatigueGeneral disorders2/42/30/32/31/32/64/73/710/210/32/36/82/614/228/20
RashSkin and subcutaneous tissue disorders1/41/31/30/30/33/65/75/713/212/32/34/83/611/226/20
Oedema peripheralGeneral disorders0/40/30/31/30/31/64/75/76/211/30/35/81/65/224/20
VomitingGastrointestinal disorders0/40/30/32/31/32/63/71/75/210/32/34/82/612/225/20
Abdominal painGastrointestinal disorders0/40/30/31/32/31/60/72/72/210/30/35/81/69/223/20
Dry skinSkin and subcutaneous tissue disorders0/41/30/32/30/31/62/73/71/211/30/31/81/62/221/20
PruritusSkin and subcutaneous tissue disorders0/42/30/30/31/31/60/71/71/210/31/31/81/61/223/20
Decreased appetiteMetabolism and nutrition disorders1/41/30/31/30/32/60/70/75/210/32/32/80/67/226/20

Baseline characteristics

Safety population consisted of all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+DextromethorphanTotal
Mean66.0 ± 11.5260.7 ± 19.7351.3 ± 6.3566.0 ± 10.8260.7 ± 9.6162.0 ± 12.3863.9 ± 5.8754.4 ± 8.4059.7 ± 13.0852.7 ± 13.2049.7 ± 21.0855.1 ± 13.4661.5 ± 13.6161.1 ± 11.4557.1 ± 15.6059.1 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1 Cohort 01 - Cobimetinib 0.05 mg/kg (21/7)Stage 1 Cohort 02 - Cobimetinib 0.10 mg/kg (21/7)Stage 1 Cohort 03 - Cobimetinib 0.20 mg/kg (21/7)Stage 1 Cohort 04 - Cobimetinib 10 mg (21/7)Stage 1 Cohort 05 - Cobimetinib 20 mg (21/7)Stage 1 Cohort 06 - Cobimetinib 40 mg (21/7)Stage 1 Cohort 07 - Cobimetinib 60 mg (21/7)Stage 1 Cohort 08 - Cobimetinib 80 mg (21/7)Stage 2 Cohort 20 - Cobimetinib 60 mg (Expansion) (21/7)Stage 1A Cohort 01A - Cobimetinib 60 mg (14/14)Stage 1A Cohort 02A - Cobimetinib 80 mg (14/14)Stage 1A Cohort 03A - Cobimetinib 100 mg (14/14)Stage 1A Cohort 04A - Cobimetinib 125 mg (14/14)Stage 2A Cohort 30 - Cobimetinib 100 mg (Expansion) (14/14)Stage 3 Cohort 40 - Cobimetinib+Midazolam+DextromethorphanTotal
Female3023132311134410959
Male13102354102042121160
08

Study locations

4 sites
  • Los Angeles, California 90095, United States
  • Stanford, California 94305-5821, United States
  • Detroit, Michigan 48201, United States
  • Buffalo, New York 14263, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2007
First posted
May 1, 2007
Start
May 2007
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Jul 22, 2016
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00467779
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 1, 2007
Start date
May 2007
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Jul 22, 2016
Last update
Aug 26, 2016

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion